Tenalisib - Rhizen Pharmaceuticals

Drug Profile

Tenalisib - Rhizen Pharmaceuticals

Alternative Names: Dual PI3K delta/gamma inhibitor - Rhizen Pharmaceuticals; RP 6530

Latest Information Update: 19 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rhizen Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cutaneous T cell lymphoma; Haematological malignancies; Peripheral T-cell lymphoma
  • Preclinical Ovarian cancer

Most Recent Events

  • 17 Apr 2018 Phase-I clinical trials in Peripheral T-cell lymphoma (Second-line therapy or greater) in USA (PO) (NCT02567656)
  • 16 Apr 2018 Tenalisib - Rhizen Pharmaceuticals receives Fast Track designation for Cutaneous T-cell lymphoma [PO] (Second-line therapy or greater) in USA
  • 09 Apr 2018 Tenalisib - Rhizen Pharmaceuticals receives Orphan Drug status for Cutaneous T-cell lymphoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top